Enovis (ENOV) reported $2.2B in revenue for fiscal 2025, +6.7% year on year. That ranks #1273 by revenue among 2853 SEC filers and #114 in Healthcare. It posted a net loss of −$1.2B for the same year. Revenue has grown 1.9% a year on average since 2017 ($1.9B then). The fiscal 2025 balance sheet shows $3.8B in total assets, $36.4M in cash and $1.3B in long-term debt.
Key figures
| Key figures | FY2025 | YoY | Source |
|---|---|---|---|
| RevenueRevenueFromContractWithCustomerExcludingAssessedTax | $2.2B | +6.7% | FY20252025-12-31 |
| Gross profitGrossProfit | $1.3B | +13.9% | FY20252025-12-31 |
| Operating incomeOperatingIncomeLoss | −$1.1B | −$349M | FY20252025-12-31 |
| Net incomeNetIncomeLoss | −$1.2B | −$359M | FY20252025-12-31 |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | $217M | +91.4% | FY20252025-12-31 |
| Capital expenditurePaymentsToAcquirePropertyPlantAndEquipment | $197M | +9.2% | FY20252025-12-31 |
| Total assetsAssets | $3.8B | −18.7% | FY20252025-12-31 |
| Shareholders' equityStockholdersEquity | $1.5B | −41.9% | FY20252025-12-31 |
| CashCashAndCashEquivalentsAtCarryingValue | $36.4M | −24.5% | FY20252025-12-31 |
| Long-term debtLongTermDebtNoncurrent | $1.3B | −3.6% | FY20252025-12-31 |
Revenue is total net sales for the fiscal year, taken from each company's own annual filing.
Reported since the last full year
Three-month figures this company has filed since FY2025. A quarter is not comparable with a full year, and these figures are used nowhere else on the site: not in any ranking, not in comparisons, not in the download.
| Quarter | Revenue | Net income | Source |
|---|---|---|---|
| Q1 20262026-04-03 | $589M | −$8.8M | Open → |
| Q2 20262026-07-03 | $583M | −$1.2M | Open → |
Only periods that end on a calendar quarter appear here. A company whose fiscal year ends in June files on a different calendar, so it has no row.
Where this sits in its sector
Each bar is the spread of the whole sector: the box covers the middle half of companies, the line inside it the median, and the triangle this company. The axis is clipped at the 5th and 95th percentile so a single outlier does not flatten it.
| Where this sits in its sector | FY2025 | Position in sector |
|---|---|---|
| Net marginRank 160 of 161 companies compared | −52.7% | |
| Operating marginRank 159 of 160 companies compared | −50.0% | |
| R&D as share of revenueRank 74 of 102 companies compared | 5.4% | |
| Cash as share of revenueRank 150 of 160 companies compared | 1.6% |
All four are ratios derived from two reported lines, not single filing items. Peer group: companies in the same sector with revenue of $1bn or more; loss-making companies are included.
Profile
- Legal name
- Enovis Corp
- Ticker
- ENOV
- Exchange
- NYSE
- SIC classification
- Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)
- Fiscal year end
- 12-31
- CIK
- 0001420800
Filings
- 10-QAug 6, 2026Open filing →
- 10-QMay 7, 2026Open filing →
- 10-KFeb 26, 2026Open filing →
Similar in size, same sector
| Company | Revenue | Net income |
|---|---|---|
| Hims & Hers HealthHIMS | $2.3B | $128M |
| ExelixisEXEL | $2.3B | $783M |
| NateraNTRA | $2.3B | −$208M |
| EnovisENOV | $2.2B | −$1.2B |
| Icu MedicalICUI | $2.2B | $732,000 |
| Sarepta TherapeuticsSRPT | $2.2B | −$713M |
| Concentra Group Holdings ParentCON | $2.2B | $166M |
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Enovis — Key figures |url=https://companiesranked.com/en/company/enovis |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Enovis — Key figures. CompaniesRanked. https://companiesranked.com/en/company/enovisBibTeX
@misc{companiesranked-en-company-enovis-2026,
author = {{CompaniesRanked}},
title = {{Enovis — Key figures}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/enovis}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-K · 0001420800-26-000012 · February 26, 2026
{{cite web |title=Enovis — Key figures — 10-K (0001420800-26-000012) |url=https://www.sec.gov/Archives/edgar/data/1420800/000142080026000012/cfx-20251231.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-02-26}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.